August 26, 2025

Regeneron to Submit Application for Cemdisiran in Myasthenia Gravis Following Positive Phase 3 NIMBLE Data

Regeneron’s cemdisiran shows promising results in treating generalized myasthenia gravis, paving the way for a potential new drug application in 2026.

August 25, 2025

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis – insights.citeline.com

August 25, 2025

With late-stage trial win, Argenx preps FDA filing to push Vyvgart into broader myasthenia gravis population – Fierce Pharma

August 25, 2025

argenx seeks broader myasthenia gravis label for Vyvgart after Phase III success – FirstWord Pharma

August 25, 2025

Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data – Neurology live